-
111.
公开(公告)号:US20230256117A1
公开(公告)日:2023-08-17
申请号:US18001648
申请日:2021-06-18
Applicant: GENETHON , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE D’EVRY-VAL-D’ESSONNE
Inventor: Isabelle RICHARD , Jerome POUPIOT
IPC: A61K48/00
CPC classification number: A61K48/0058
Abstract: The present invention concerns an expression system for systemic administration comprising a sequence encoding gamma-sarcoglycan (SGCG) placed under the control of a promoter allowing an adequate expression of SGCG in the skeletal muscles and in the heart, and its use for the treatment of Limb-Girdle Muscular Dystrophy type C.
-
112.
公开(公告)号:US20230242905A1
公开(公告)日:2023-08-03
申请号:US18013339
申请日:2021-07-05
Applicant: Genethon , Institut National de la Santé et de la Recherche Médicale , Universite d'Evry Val d'Essonne
Inventor: Giuseppe Ronzitti , Tiziana Labella
CPC classification number: C12N15/1082 , C12N15/86 , C12N2750/14122 , C12N2750/14143 , C12N2750/14145 , C12N2750/14152
Abstract: The invention relates to a method of preparation of a recombinant hybrid adeno-associated virus (AAV) capsid protein with improved tropism and to the recombinant hybrid AAV capsid protein obtainable by the method. The invention relates also to the derived expression vector, modified cell, and hybrid capsid AAV vector particle packaging a gene of interest, and its use in tissue-targeted gene therapy for treating various diseases.
-
公开(公告)号:US20230203537A1
公开(公告)日:2023-06-29
申请号:US17929816
申请日:2022-09-06
Applicant: UNIVERSITE D'EVRY VAL D'ESSONNE , GENETHON , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÈDICAL)
Inventor: Anne GALY
IPC: C12N15/86 , A61K35/76 , C07K14/005 , C12N5/0781 , A61K35/17
CPC classification number: C12N15/86 , A61K35/76 , C07K14/005 , C12N5/0635 , A61K35/17 , A61K48/00
Abstract: The present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps:
a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the gene of interest, the rev, gag and pol genes, and a sequence coding for an ERV syncytin, wherein the rev, gag and pol genes are retroviral genes;
b) incubating the transfected cells obtained in a), so that they produce the stable pseudotyped lentiviral particles in the supernatant; and
c) harvesting and concentrating the stable lentiviral particles obtained in b).
The present invention also relates to a method to transduce immune cells using lentiviral vectors pseudotyped with an ERV syncytin glycoprotein. The method can be performed on non-stimulated blood cells or on cells stimulated briefly with IL7, and the cells can be expanded.
The stable pseudotyped lentiviral particles obtained are particularly useful in gene therapy.-
114.
公开(公告)号:US20230142731A1
公开(公告)日:2023-05-11
申请号:US17862622
申请日:2022-07-12
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , GENETHON , SORBONNE UNIVERSITÉ , UNIVERSITÉ DE PARIS , SPARK THERAPEUTICS, INC.
Inventor: Sébastien LACROIX-DESMAZES , Federico MINGOZZI , Jordan DIMITROV , Christian LEBORGNE , Sean ARMOUR
IPC: A61K48/00 , C12N9/24 , C12N15/113 , C12N15/86 , A61K38/48 , C12N9/64 , C12N15/861
CPC classification number: A61K48/005 , C12N9/2402 , C12N15/113 , C12N15/86 , A61K38/4873 , C12N9/6475 , C12N15/861 , C12N2310/11 , C12N2310/141 , C12N2750/14143 , C12Y302/01 , C12Y304/22 , C12Y304/2201 , G01N33/6854
Abstract: Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.
-
公开(公告)号:US20230117384A1
公开(公告)日:2023-04-20
申请号:US17750705
申请日:2022-05-23
Applicant: GENETHON , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE D'EVRY VAL D'ESSONNE
Inventor: Saliha MAJDOUL , David FENARD
Abstract: The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.
-
公开(公告)号:US11596698B2
公开(公告)日:2023-03-07
申请号:US16628650
申请日:2018-07-06
Applicant: GENETHON , UNIVERSITE D'EVRY-VAL-D'ESSONNE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Inventor: Isabelle Richard , Evelyne Gicquel-Zouida , William Lostal
Abstract: The present invention concerns synthetic polynucleotides encoding a human fukutin-related protein (FKRP) wherein the synthetic polynucleotides contain at least a mutation avoiding supplementary transcript(s) generated from frameshift start codon(s). The synthetic polynucleotides are useful, especially for treating a pathology linked to a FKRP deficiency or induced by a defect in α-dystroglycan (α-DG) glycosylation, such as LGMD2I.
-
公开(公告)号:US20230033268A1
公开(公告)日:2023-02-02
申请号:US17770641
申请日:2020-10-22
Applicant: GENETHON , UNIVERSITE D'EVRY VAL D'ESSONNE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , SORBONNE UNIVERSITE
Inventor: PASQUALINA COLELLA , FRANCESCO PUZZO , FEDERICO MINGOZZI
Abstract: The present invention relates to a nucleic acid molecule encoding a chimeric polypeptide comprising a peptide of interest fused to one or more heterologous moieties, wherein at least one of the heterologous moieties is a ligand of the Sortilin receptor. The invention also relates to a chimeric polypeptide encoded by said nucleic acid molecule and uses thereof.
-
公开(公告)号:US11427824B2
公开(公告)日:2022-08-30
申请号:US16345743
申请日:2017-10-27
Inventor: Ana Maria Buj Bello , Mirella Lo Scrudato
IPC: C12N15/113 , A61P21/00 , C12N9/22 , C12N15/10 , C12N15/90
Abstract: The present invention relates to compositions and methods for the treatment of myotonic dystrophy.
-
公开(公告)号:US20220213505A1
公开(公告)日:2022-07-07
申请号:US17610840
申请日:2020-05-15
Applicant: UNIVERSITÉ DE PARIS , GENETHON , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Inventor: Federico MINGOZZI , Jean DAVOUST , Laurent BARTOLO
Abstract: A combination of two recombinant adeno-associated viral (rAAV) vectors comprising in the first a capsid and a cassette comprising a 5′ ITR sequence, a liver-specific promotor, a nucleic acid sequence coding for a transgene of interest useful to be tolerated by the immune system and a poly A chain and in the second a capsid and a cassette comprising a 5′ ITR sequence, a promotor specific for a tissue of interest, a nucleic acid sequence corresponding to the nucleic acid sequence inserted into the cassette of the first rAAV vector, a transmembrane sequence, a poly A chain, wherein the nucleic acid sequences is administered towards to the tissue of interest, is disclosed. Said combination can be used in inducing an immune tolerance to a protein product encoded, and so be used as a drug in a subject, particularly for treating muscular dystrophies. Pharmaceutical compositions, kits and methods are also disclosed.
-
公开(公告)号:US11376321B2
公开(公告)日:2022-07-05
申请号:US16490181
申请日:2018-03-01
Applicant: GENETHON , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , SORBONNE UNIVERSITÉ , ASSOCIATION INSTITUT DE MYOLOGIE
Inventor: Bérangére Bertin , Carole Masurier , Otto-Wilhelm Merten , Federico Mingozzi
IPC: A61K39/235 , A61M1/36 , C07K16/06 , C07K16/08 , C12N7/00
Abstract: The present invention relates to a method for removing undesired anti-AAV antibodies from a blood-derived composition.
-
-
-
-
-
-
-
-
-